Formation Bio Expands Leadership Team with Industry Veterans

Formation Bio has announced the appointment of four experienced executives to its leadership team to bolster its AI-driven drug development initiatives, announced in a press release. The new appointees include Louis Brenner, MD, as Chief Medical Officer; Daniel Neil, PhD, as Chief Technology Officer; and Frank D'Amelio and Dashyant Dhanak, PhD, as Senior Advisors.

Louis Brenner, MD, brings over 20 years of experience in biotech and pharma, having previously served as President and CEO of Hopewell Therapeutics. Daniel Neil, PhD, joins as Chief Technology Officer with a strong background in machine learning and AI, having led AI/ML strategies at Tessera Therapeutics and BenevolentAI.

Frank D'Amelio, with nearly 15 years as Chief Financial Officer at Pfizer, joins as a Strategic Advisor. Dashyant Dhanak, PhD, who has held senior roles at Incyte and BenevolentAI, will also serve as a Strategic Advisor. These appointments aim to strengthen Formation Bio's capabilities in clinical, technological, financial, and scientific domains as it scales its AI-native pharma model.